J. Hardy

Severe obesity is associated with liver disease severity in pediatric non‐alcoholic fatty liver disease

M. Mouzaki, A. Trout, Chunyan Liu, 2020, Pediatric obesity.

A Review on the Efficacy and Safety of Oral Semaglutide

M. Sheikh-Ali, D. Sutton, J. Hardy, 2021, Drugs in R&D.

A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent

Jessica H. Huston, J. Hardy, M. Ashchi, 2021, American Journal of Cardiovascular Drugs.

A Critical Review of the Efficacy and Safety of Inclisiran

J. Hardy, R. Choksi, J. Reid, 2021, American Journal of Cardiovascular Drugs.

Do the honeybee pathogens Nosema ceranae and deformed wing virus act synergistically?

S. Martin, M. Higes, R. Martín-Hernández, 2013, Environmental microbiology reports.

Extremely low levels of low-density lipoprotein potentially suggestive of familial hypobetalipoproteinemia: A separate phenotype of NAFLD?

Amy S. Shah, M. Mouzaki, S. Xanthakos, 2019, Journal of clinical lipidology.

Australian Health Review

James M. Canty, Jenni K. Gratton-Vaughan, Raymond F. Peterson, 2004 .

Danuglipron. Glucagon-like peptide 1 receptor agonist, Treatment of type 2 diabetes, Treatment of obesity

M. Sheikh-Ali, D. Sutton, J. Hardy, 2022, Drugs of the Future.